Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
This settlement is closed!
Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!
Indivior agreed to a $30 million antitrust class action lawsuit settlement to resolve claims that it worked with other companies to raise the cost of Suboxone, a treatment for opioid addiction.
The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 201,1 and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia.
The antitrust class action lawsuit accused Indivior of conspiring with other companies to raise the price of Suboxone and its generic alternatives. According to the plaintiffs in the case, they were forced to overpay for Suboxone as a result of the antitrust scheme.
Individor is a pharmaceutical company that specializes in addiction and mental health treatment.
Indivior hasn’t admitted any wrongdoing but agreed to a $30 million settlement to resolve the antitrust class action lawsuit.
Under the terms of the Suboxone class action settlement, class members can receive a proportional share of the net settlement fund based on the amount they spent in qualifying purchases. Exact payments will vary depending on the number of claims filed and other factors.
The deadline for exclusion is Oct. 12, 2023. The objection deadline is Oct. 5, 2023.
The final approval hearing for the Suboxone antitrust class action lawsuit settlement is scheduled for Oct. 19, 2023.
In order to receive a settlement payment, class members must submit a valid claim form by Feb. 17, 2024.
Who’s Eligible
Individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011, and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia
Potential Award
Varies
Proof of Purchase
Records from the class member’s pharmacy showing they purchased Suboxone and its AB‐rated generic equivalents at least once or a note or records from their doctor describing the amount of Suboxone and its AB‐rated generic equivalents prescribed.
Class members may have a claim even if they are not able to provide any of the above claim documentation as long as they provide the certification on the claim form. However, the settlement administrator may ask those who do not provide the above documentation for additional claim documentation after the class member submits their claim form.
Claim Form
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
02/17/2024
Case Name
In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, Case No. 2:13-md-02445-MSG, in the U.S. District Court for the Eastern District of Pennsylvania
Final Hearing
10/19/2023
Settlement Website
Claims Administrator
Suboxone End-Payor Antitrust Litigation
c/o A.B. Data, Ltd.
P.O. Box 173080
Milwaukee, WI 53217
info@SuboxAntitrust.com
877-311-3735
Class Counsel
Kenneth A Wexler
WEXLER BOLEY & ELGERSMA LLP
Steve Shadowen
HILLIARD SHADOWEN LLP
Michael M. Buchman
MOTLEY RICE LLC
Marvin A Miller
MILLER LAW LLC
Jeffrey L Kodroff
SPECTOR ROSEMAN & KODROFF PC
Defense Counsel
Justin Bernick
HOGAN LOVELLS US LLP
Read About More Class Action Lawsuits & Class Action Settlements:
- CVS lidocaine false advertising $3.8M class action settlement
- Allwell Behavioral Health data breach $650K class action settlement
- Right Guard antiperspirant $1.95M class action settlement
- Instagram BIPA $68.5M class action settlement
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
131 thoughts onSuboxone indirect purchasers antitrust $30M class action settlement
I took suboxzone for around 5 years and I just found about the lawsuit. I’m too late to qualify. Ii really hate that Because I spent a lot of money for the monthlyDr. Bills and the cost of the medication was expensive at that time. If there’s a way for me to.still qualify please let me know. Thank you 😊